ZURA
NASDAQ · Biotechnology
Zura Bio Ltd
$4.10
+0.06 (+1.49%)
Open$4.03
Previous Close$4.04
Day High$4.19
Day Low$3.92
52W High$7.44
52W Low$2.01
Volume—
Avg Volume1.85M
Market Cap359.39M
P/E Ratio—
EPS$-0.79
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+463.9% upside
Current
$4.10
$4.10
Target
$23.12
$23.12
$15.51
$23.12 avg
$31.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 178.15M | 170.40M | 174.38M |
| Net Income | 4.79M | 4.86M | 5.73M |
| Profit Margin | 2.7% | 2.9% | 3.3% |
| EBITDA | 8.96M | 8.92M | 9.38M |
| Free Cash Flow | 5.34M | 5.40M | 5.82M |
| Rev Growth | +24.5% | +6.4% | +20.2% |
| Debt/Equity | 0.26 | 0.34 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |